Przychodnia Alergologiczno-Pulmonologiczna Alergopneuma Sp. z o.o.

Clinical research at Przychodnia Alergologiczno-Pulmonologiczna Alergopneuma focuses on severe eosinophilic asthma, aiming to reduce exacerbations and improve patient outcomes.

• Evaluation of dexpramipexole’s impact on exacerbation frequency
• Long‑term safety monitoring in adult and adolescent participants
• Assessment of quality‑of‑life improvements

The studies seek to provide new therapeutic options for individuals struggling with high‑risk asthma phenotypes.

Investigations target mild to moderate asthma, comparing inhaled formulations to determine equivalent efficacy in lung function.

• Therapeutic equivalence of CHF5993 pMDI HFA‑152a versus HFA‑134a
• Measurement of forced expiratory volume (FEV1) changes over 4‑hour intervals
• Evaluation of pre‑dose lung function after four weeks of treatment

Results aim to expand treatment choices for patients with controlled or partly controlled disease.

The site conducts broader research on pulmonary function to enhance diagnostic and therapeutic strategies for respiratory tract diseases.

• Impact of novel agents on FEV1 and other spirometric parameters
• Correlation of eosinophil levels with treatment response
• Integration of patient‑reported outcomes in clinical assessment

These efforts support the development of more precise and effective asthma management approaches.